Yuceer, Ramazan OguzKaya, SeyhmusBalci, Sema NurEgilmez, Hatice ReyhanYilmaz, MukaddesErdis, Eda2025-05-042025-05-0420252076-3425https://doi.org/10.3390/brainsci15020212https://hdl.handle.net/20.500.12418/35204Background: Isocitrate dehydrogenase (IDH) wild-type (wt) glioblastoma is an aggressive malignancy associated with poor clinical outcomes, marked by high heterogeneity and resistance to treatment. This study aims to investigate the prognostic significance of B7-H3 expression in IDH wt glioblastoma and its potential association with clinical outcomes, including overall survival (OS) and progression-free survival (PFS). Additionally, the relationship between B7-H3 and PD-L1 expression was explored. Methods: A retrospective cohort of 86 IDH wt glioblastoma patients, all of whom underwent surgery, radiotherapy, and temozolomide treatment, was analyzed. B7-H3 expression was quantified using an immunoreactivity score (IRS), classifying samples as low (IRS <= 4) or high (IRS > 4). PD-L1 expression was evaluated based on tumor and immune cell staining, with >5% positivity indicating significant expression. Results: High B7-H3 expression was significantly associated with poorer OS and PFS. Co-expression of B7-H3 and PD-L1 was prevalent, particularly among younger male patients with unifocal tumors; however, PD-L1 expression did not show a significant correlation with clinical outcomes. Conclusions: B7-H3 appears to be a promising prognostic biomarker in IDH wt glioblastoma and may serve as a target for developing combination therapies, integrating B7-H3-targeting treatments with immune checkpoint inhibitors. Further prospective studies are necessary to validate these findings and to explore potential therapeutic strategies.en10.3390/brainsci15020212info:eu-repo/semantics/openAccessglioblastomaB7-H3PD-L1immune checkpointsurvivalIDH wild typebrain tumorbiomarkerCD276adult-type diffuse gliomaArticle152400025432-s2.0-85218676636Q3WOS:001432257600001Q3